10 results about "Hematological Tumor" patented technology

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

This invention belongs to the fields of medicinal chemistry and pharmaceutical technology, and relates to 1,4-benzodiazepines and their use in the preparation of antitumor drugs, specifically the use of 1,4-benzodiazepines in the preparation of annexin A3 (ANXA3) degrading agents and in the preparation of drugs for treating cancer. In particular, it discloses the use of 1,4-benzodiazepines, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or compositions of drugs with these as active ingredients, in the preparation of drugs for the prevention and treatment of tumors. These compounds can bind to the ANXA3 protein, induce ANXA3 protein degradation, inhibit the proliferation, cloning, migration, and invasion of tumor cells, and exert antitumor therapeutic effects in vivo. They can be used to treat solid tumors and hematological malignancies, including breast cancer, cervical cancer, ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, esophageal cancer, liver cancer, leukemia, and melanoma.

The present application relates to the technical field of medical devices, in particular to a wound debridement device for blood tumor patients, comprising a handle vertically arranged, an injection part, an adsorption part and a mounting part for clamping medical cotton, the lower end of the handle is provided with a placing cavity, the mounting part is arranged in the placing cavity, the injection part comprises a first cylindrical cavity, a first button, a vertical slide and a first flow channel arranged in the handle, the mounting part comprises a fixing block arranged in the placing cavity and detachably connected with the handle, when the medical cotton is clamped on the handle by the fixing block, part of the medical cotton extends out of the lower end of the handle through the center hole of the fixing block, and the adsorption part comprises a second cylindrical cavity, a second button and an adsorption channel arranged vertically. The present application is simple and fast in operation when debriding the wound of the patient, greatly shortens the debridement time and reduces the labor intensity of medical staff, simultaneously reduces the time of exposing the wound of the patient to the outside, reduces the risk of wound infection and improves the wound healing speed.

This application provides a method and related equipment for constructing a clonal evolution atlas of hematologic malignancies. The method includes acquiring batch sequencing data and extracting a set of complementarity-determining region (CDR) sequences from the batch sequencing data; filtering the CDR sequence set for pseudoclones to obtain a first sequence set; clustering the CDR sequences in the first sequence set based on edit distance to obtain multiple clonal clusters; performing evolutionary co-validation on clonal pairs in the clonal clusters at multiple time points to obtain an evolutionary trend score; filtering the clonal clusters at multiple time points based on the evolutionary trend score to obtain a clonal evolution time series; and constructing a clonal evolution atlas based on the clonal evolution time series. This method can improve the accuracy of the constructed clonal evolution.

The application belongs to the field of medicine, and relates to application of a pyrrolopyridine-containing compound in treatment of tumors, in particular to application of a compound of formula (I-1) or a pharmaceutically acceptable salt thereof in treatment of hematological tumors, wherein the hematological tumors are selected from relapsed and / or refractory hematological tumors

The present application relates to the technical field of drug evaluation, and discloses a kind of blood tumor targeted drug curative effect dynamic evaluation method and system.The method comprises: by obtaining the feedback parameter containing action index and physiological index after targeted drug administration, and the difference calculation of feedback parameter and the benchmark feedback parameter under the condition of not being administered to output deviation parameter, and then generate drug efficacy fluctuation signal or risk early warning signal;And generate curative effect evaluation report based on drug efficacy fluctuation signal or risk early warning signal.The present application realizes the dynamic quantitative evaluation of curative effect by establishing the benchmark control of patient itself, objectively reflects the net effect of drug on patient, provides reliable individualized data basis for curative effect evaluation, improves the objectivity and accuracy of evaluation;And by filtering out random noise and transient fluctuation in data, ensure that the identified change starting point has high confidence, improve the accuracy and reliability of key event capture in dynamic evaluation process.

The present application relates to the technical field of medical image processing, and provides a precancerous lesion of oral leukoplakia early warning system and method, comprising: establishing an association model of oral leukoplakia image features and blood tumor marker time series, when the last sampling points of the two are not synchronized, generating predictive blood risk representation data based on the current leukoplakia image features; constructing a cross-modal time series trajectory according to the leukoplakia image features and blood tumor marker time series collected multiple times, identifying abnormal trajectory patterns; and generating a precancerous lesion risk level of oral leukoplakia accordingly. The present application effectively solves the information fault problem caused by the asynchronization of image data and blood data sampling time points, and improves the real-time performance and accuracy of risk assessment.

The present invention relates to a trispecific antibody specifically binding to CD19, CD3, and CD28, which trispecific antibody contains a fragment derived from an IgD hinge region as a linker. The present invention also relates to the use of the trispecific antibody for treating tumors such as malignant hematological tumors.

The application discloses a blood tumor diagnosis and treatment primer group, a kit and application, the primer group comprises a first primer group and / or a second primer group; the first primer group is used for amplifying IGH, IGDH, IGK and IGL; the second primer group is used for amplifying TRB V-J, TRB D-J, TRG and TRD, after the primer group amplification reordering sequence, the positive detection of a clinical sample can be significantly improved, the CDR3 sequence obtained can be used for clinical monitoring and can independently evaluate the immune group of each patient, accurately reflects the immune state of the individual, dynamically monitors the change of the tumor cells of the patient, and has good reliability and repeatability.

Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.